Neogene Therapeutics is now a part of the AstraZeneca Group. Visit AstraZeneca.com AstraZeneca.com

Neogene Therapeutics is developing both patient-specific and shared neoantigen TCR programs to introduce such TCRs into a patient’s own T cells, redirecting their antigen specificity.

Sign in with Neogene Sign in with AstraZenecaNeogene T-Cell Processing

Carsten Linnemann, Ph.D., is the President, Chief Executive Officer, and a Co-Founder of Neogene Therapeutics. Before Neogene, Dr. Linnemann served as Associate Director, Next Generation T Cell Therapies and Managing Director of Kite Pharma EU B.V.

Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies

US Headquarters Neogene Therapeutics, Inc. 2225 Colorado Ave Santa Monica, CA 90404 United States

The post Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumorsappeared first on Neogene Therapeutics.